<DOC>
	<DOCNO>NCT01340573</DOCNO>
	<brief_summary>This non-interventional study design evaluate efficacy safety combination study drug treatment participant diagnose Chronic Hepatitis C ( CHC ) . CHC participant confirm positive hepatitis-C virus ( HCV ) RNA plasma , previously treat Pegylated interferon ( PegIntron ) Pen , enrol study .</brief_summary>
	<brief_title>Evaluating Safety Efficacy In Hepatitis C Patients After PegIntron Pen Treatment ( Study P04896 )</brief_title>
	<detailed_description>Participants positive genotype-1 HCV RNA receive 48 week treatment PegIntron Pen plus ribavirin 24 week follow-up . Participants non-genotype-1 HCV RNA positive receive 24 week treatment PegIntron Pen plus ribavirin 24 week follow-up . Participants ask complete questionnaire measure satisfaction use training material PegIntron pen use 1-5 score system provide questionnaire . The questionnaire complete first follow-up visit . Efficacy measurement sustain viral response HCV RNA collect week-24 treatment week-24 follow-up positive Non-genotype-1 HCV RNA participant . Efficacy measurement sustain viral response HCV RNA collect week-24 week-48 treatment , week-24 follow-up , positive Genotype-1 HCV RNA participant .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Demonstrate willingness participate study comply procedure sign write informed consent . Equal great 18 year . Confirmed chronic hepatitis C hepatitis C virus ( HCV ) RNA positive plasma . No previous use PegIntron Pen . Hypersensitivity active substance interferon excipients . Pregnant woman . Women breastfeed . Existence history severe psychiatric condition , particularly severe depression , suicidal ideation suicide attempt . A history severe preexist cardiac disease , include unstable uncontrolled cardiac disease previous six month . Severe debilitate medical condition , include patient chronic renal failure creatinine clearance &lt; 50 ml/minute . Auto immune hepatitis history autoimmune disease . Severe hepatic dysfunction decompensated cirrhosis liver . Preexisting thyroid disease unless controlled conventional treatment . Epilepsy and/or compromise central nervous system ( CNS ) function .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Chronic Hepatitis C</keyword>
	<keyword>pegylated interferon</keyword>
	<keyword>PegIntron Pen</keyword>
	<keyword>Ribavirin</keyword>
</DOC>